- TRADE NAME: Alunbrig (Ariad)
- INDICATIONS: Anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in patients who have progressed on, or are intolerant to, crizotinib
- CLASS: Anaplastic lymphoma kinase (ALK) inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: 25 hours
- FDA APPROVAL DATE: 04/28/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Boceprevir, Carbamazepine, Clarithromycin, Cobicistat, Conivaptan, CYP3A substrates and strong CYP3A inducers or inhibitors, Grapefruit Juice, Hormonal contraceptives, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Nelfinavir, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Voriconazole - PREGNANCY: May cause fetal toxicity based on findings in animal studies
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 02/28/2025
